Sunshine Biopharma Inc (SBFM)

[Screech691]

SBFM Ultimate DD

Sunshine Biopharma is focused on the research, development and commercialization of drugs for the treatment of various forms of cancer.

http://sunshinebiopharma.com/index.html


Our Proprietary Technology

Many therapeutically important compounds contain diester bonds that link different parts of the molecule together. Diester bonds are naturally unstable often leading to suboptimal performance when the molecule is administered to patients. Diester bonds have specific electrostatic properties and three-dimensional structure that cannot be easily mimicked by other bonds. Chemical structures that do not mimic the diester bond correctly invariably render the compound biologically inactive. In collaboration with Institut National des Sciences Appliquées de Rouen in France (“INSA”), our licensor, Advanomics Corporation, has developed a way to replace the diester bond with a Carbon-Difluoride bond which acts as a perfect diester isostere. An isostere is a different chemical structure that mimics the properties of the original. In the body, Carbon-Difluoride compounds are resistant to metabolic degradation but are recognized similarly to the diester containing compounds (see Figure below). This technology allows us to create a large variety of therapeutic compounds that are completely stable and often more active than the original drugs.

This unique capability allowed us to create our Lead Compound, Adva-27a, an effective and highly specific Topoisomerase II (Top2) Inhibitor. Our in vitro studies have shown that Adva-27a is very effective at killing a variety of cancer types including Multi-Drug Resistant Breast Cancer.

The Company is planning to expand its product line through acquisitions and/or in-licensing as well as in-house research & development.

http://sunshinebiopharma.com/technology.html

Recent News:

08/30/2011 -
Clearance of Sunshine Biopharma's Anti-Cancer Compound, Adva-27a, Does Not Involve a Toxic Intermediate
http://sunshinebiopharma.com/Pr_Rel_8-23_Podophyllotoxin_V2_Final.pdf

07/27/2011 -
Sunshine Biopharma Looking to Mimic Roche's Billion Dollar Cancer Drug Success
http://sunshinebiopharma.com/PressArticleSunshineBiopharmaLookingToMimicRoche.pdf

07/25/2011 -
Sunshine Biopharma's Lead Anti-tumor Compound, Adva-27a, is cleared via a cytochrome P450-Independent Mechanism
http://sunshinebiopharma.com/Pr_Rel_7-18_CytochromeP450_V4_FINAL.pdf

07/11/2011 -
Sunshine Biopharma’s Adva-27a is 16-times more effective at killing multidrug resistant breast cancer cells
http://sunshinebiopharma.com/Pr%20Rel%20Cytotoxicity%207-11_Andy_Steve_V4_Clean.pdf

06/27/2011 -
Sunshine Biopharma's Lead Anti-Cancer Compound, Adva-27a, performs exceptionally well in human microsome stability assays
http://sunshinebiopharma.com/Pr_Rel_6-24_MICROSOME_V3_FINAL.pdf

06/17/2011 -
Sunshine Biopharma enters into clinical trials agreement with the Jewish General Hospital in Montreal, Canada
http://sunshinebiopharma.com/Pr_Rel_6-11_JGH_V2_FINAL.pdf

SBFM Security Details


Share Structure
Market Value1 $15,662,784 a/o Oct 03, 2011
Shares Outstanding 30,711,342 a/o May 10, 2011
Float Not Available
Authorized Shares Not Available
Par Value No Par Value